JP2007209324A - Method for producing iron supplement composition - Google Patents
Method for producing iron supplement composition Download PDFInfo
- Publication number
- JP2007209324A JP2007209324A JP2006064834A JP2006064834A JP2007209324A JP 2007209324 A JP2007209324 A JP 2007209324A JP 2006064834 A JP2006064834 A JP 2006064834A JP 2006064834 A JP2006064834 A JP 2006064834A JP 2007209324 A JP2007209324 A JP 2007209324A
- Authority
- JP
- Japan
- Prior art keywords
- iron
- acid
- supplement composition
- raw material
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 223
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 107
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 239000013589 supplement Substances 0.000 title claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 36
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 36
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 150000007524 organic acids Chemical class 0.000 claims abstract description 19
- 241000894006 Bacteria Species 0.000 claims abstract description 18
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims abstract description 13
- 240000006439 Aspergillus oryzae Species 0.000 claims abstract description 13
- 239000004310 lactic acid Substances 0.000 claims abstract description 12
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 12
- 235000011054 acetic acid Nutrition 0.000 claims abstract description 11
- 235000015165 citric acid Nutrition 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008213 purified water Substances 0.000 claims abstract description 8
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 6
- 239000001630 malic acid Substances 0.000 claims abstract description 6
- 235000011090 malic acid Nutrition 0.000 claims abstract description 6
- 239000011975 tartaric acid Substances 0.000 claims abstract description 6
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 6
- 230000032683 aging Effects 0.000 claims abstract description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 238000000855 fermentation Methods 0.000 claims description 14
- 230000004151 fermentation Effects 0.000 claims description 14
- 239000002211 L-ascorbic acid Substances 0.000 claims description 7
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 238000010025 steaming Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 239000003792 electrolyte Substances 0.000 abstract description 5
- 208000007502 anemia Diseases 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 230000002411 adverse Effects 0.000 abstract 2
- 238000010411 cooking Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 229940082629 iron antianemic preparations Drugs 0.000 description 6
- 150000003278 haem Chemical class 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002431 foraging effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- -1 iron ions Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- FNTOMPCYJCXKDL-UHFFFAOYSA-N 3-(3-hydroxy-4-nitroso-n-propylanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CCC)C1=CC=C(N=O)C(O)=C1 FNTOMPCYJCXKDL-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Abstract
Description
この発明は、鉄補給組成物の製造方法に関するものであり、一層詳細には、吸収性が良くしかも副作用の少ない鉄補給組成物の製造方法に関するものである。 The present invention relates to a method for producing an iron supplement composition, and more particularly to a method for producing an iron supplement composition having good absorbability and few side effects.
鉄Feは成人の体内に2g〜4g含まれており、主に血液中の赤血球のヘモグロビン、筋肉のミオグロビン及び肝臓のフェリチンなどに蓄えられ、一部は全身の細胞に広く分布している微量金属元素である。
通常、鉄は食物の形態として摂取されたのち、消化管内でFe2+やFe3+のイオンとして遊出し、一部はフェリチンおよびFe3+として血漿中に存在するが大部分はヘモグロビンの形成にあずかることが知られている。Iron Fe is contained in adult body 2g-4g, and is stored mainly in erythrocyte hemoglobin, muscle myoglobin, liver ferritin, etc. in the blood, and some of them are widely distributed in cells throughout the body. It is an element.
Usually, iron is ingested as a form of food, and then it is released as Fe 2+ and Fe 3+ ions in the digestive tract, some of which are present in the plasma as ferritin and Fe 3+ , but most are involved in the formation of hemoglobin It has been known.
ヘモグロビンの鉄は酸素を運搬し、ミオグロビンの鉄は血中の酸素を細胞に取り入れる。そして各細胞の鉄は、酸素の活性化や栄養素の燃焼など体内の酸化還元反応に極めて重要な役割を果たしている。 Hemoglobin iron carries oxygen, and myoglobin iron takes oxygen from the blood into cells. The iron in each cell plays an extremely important role in the oxidation-reduction reactions in the body, such as oxygen activation and nutrient combustion.
このように鉄は生体上必要不可欠な金属であるが、消化管障害、代謝性疾病の罹患、月経などによる鉄欠乏性貧血は頻繁に発生しており、これらへの対処として、無機の鉄化合物あるいは有機の鉄化合物を有効成分とする鉄製剤(鉄補給組成物)が、注射、経口投与などにより利用されている。 In this way, iron is an indispensable metal in the living body, but iron deficiency anemia due to gastrointestinal tract disorders, metabolic diseases, menstruation, etc. frequently occurs. Or the iron formulation (iron supplement composition) which uses an organic iron compound as an active ingredient is utilized by injection, oral administration, etc.
これらのうち、無機の鉄製剤は、胃内で速やかにイオン化するため、胸焼け・嘔吐などのほか胃粘膜びらん・潰瘍等の消化管障害を惹起し、特に感受性の高い幼児においては中毒を引き起こすことが報告されている。
また、有機の鉄製剤は、無機の鉄製剤に見られるような副作用は低減しているものの、高用量を摂取しないと目的とする鉄補給効果が得られないことやコスト高につながることもあり、いずれの鉄製剤にも課題があるのが実情である。Among these, inorganic iron preparations quickly ionize in the stomach, causing heartburn, vomiting, and other gastrointestinal disorders such as gastric mucosal erosion and ulcers, and cause poisoning in particularly sensitive infants. Has been reported.
In addition, organic iron preparations have reduced side effects as seen in inorganic iron preparations, but unless high doses are taken, the intended iron supplementation effect may not be achieved and costs may increase. In fact, all iron preparations have problems.
一方、多孔性基材の隙間に硫酸第一鉄などの無機鉄を配合するとともにこれをコーティングして無機鉄が徐々に放出されるようにして副作用を軽減するようにした徐放性の鉄製剤も開発されている。
しかしながら、このような鉄製剤は徐放性の付与に伴って溶解性が低下するため、所望の鉄補給効果を得るには高用量を摂取することになり、また食品に添加すると容易にイオン化して、無機の鉄製剤と同様の副作用を引き起こすことがあった。On the other hand, a sustained release iron preparation that contains inorganic iron such as ferrous sulfate in the gap between porous substrates and coats it to gradually release inorganic iron to reduce side effects. Has also been developed.
However, since the solubility of such iron preparations decreases with the provision of sustained release, a high dose is taken to obtain the desired iron supplementation effect, and ionization easily occurs when added to foods. In some cases, side effects similar to those of inorganic iron preparations were caused.
このような事情から、鉄を効果的に生体に補給でき副作用も伴わない鉄製剤(鉄補給組成物)の開発が期待されている。 Under such circumstances, development of an iron preparation (iron supplement composition) that can effectively replenish iron to a living body and has no side effects is expected.
そこで、本発明ではこの課題を解決するため、わが国で古くから行われている発酵技術に着目し、原料として適宜の手段で微細化した鉄を醗酵させ、ついでこれに有機酸を混合して熟成することにより、有機酸と鉄が解離している電解質状態の鉄補給組成物として構成するものである。 Therefore, in the present invention, in order to solve this problem, attention is paid to fermentation techniques that have been performed in Japan for a long time, fermented iron as a raw material by an appropriate means, and then mixed with an organic acid for aging By doing so, it is configured as an iron supplement composition in an electrolyte state in which the organic acid and iron are dissociated.
具体的には、微細化した鉄原料に所定量の浄化水を加えて蒸煮殺菌し、つぎにこれに麹菌と糖質を加えて一次醗酵させたのち、麹菌、酵母、クエン酸菌、乳酸菌、酢酸菌を単独でまたはこれらの2種以上の混合物と糖質を加えて二次醗酵させ、さらにこの醗酵鉄原料にクエン酸、乳酸、酢酸、酒石酸、リンゴ酸から選ばれるカルボキシル基を有する有機酸を単独でまたはこれらの2種以上の混合物を混合して35℃〜45℃の温度に保持して熟成し、さらにこれを濾過抽出することを特徴とするものである。 Specifically, a predetermined amount of purified water is added to the refined iron raw material and sterilized by steaming. Next, koji molds and saccharides are added thereto, followed by primary fermentation, koji molds, yeast, citric acid bacteria, lactic acid bacteria, Acetic acid bacteria alone or a mixture of two or more of them and a saccharide are subjected to secondary fermentation, and the fermented iron raw material has a carboxyl group selected from citric acid, lactic acid, acetic acid, tartaric acid and malic acid. Singly or in a mixture of two or more of these, and kept at a temperature of 35 ° C. to 45 ° C. for aging, and further filtered and extracted.
この場合、醗酵鉄原料を熟成する際に、醗酵鉄原料に対して1重量%〜8重量%のL−アスコルビン酸(ビタミンC)を加えるのが好ましい。 In this case, it is preferable to add 1% by weight to 8% by weight of L-ascorbic acid (vitamin C) with respect to the fermented iron raw material when aging the fermented iron raw material.
また、この熟成に際しては、遠赤外線照射およびエレクトロン供給雰囲気において醗酵鉄原料を流動させながら行うのが好適である。 Further, this aging is preferably carried out while allowing the fermented iron raw material to flow in a far-infrared irradiation and electron supply atmosphere.
さらに、本発明は上記製造方法により得られた鉄補給組成物も包含するものである。 Furthermore, the present invention also includes an iron supplement composition obtained by the above production method.
本発明に係る鉄補給組成物の製造方法によれば;
(1)微細化した鉄原料と浄化水に麹菌と糖質を加えて一次醗酵させたのち、麹菌、酵母、クエン酸菌、乳酸菌、酢酸菌を単独でまたはこれらの2種以上の混合物と糖質を加えて二次醗酵させ、さらにこの醗酵鉄原料にクエン酸、乳酸、酢酸、酒石酸、リンゴ酸から選ばれるカルボキシル基を有する有機酸を単独でまたはこれらの2種以上の混合物を混合して35℃〜45℃の温度に保持して熟成し、さらにこれを濾過抽出することにより有機酸と鉄が解離している電解質の状態として構成するので吸収性が良く副作用の伴なわない鉄補給組成物を得ることができる。
(2)醗酵鉄原料に有機酸を加えて熟成する際、鉄の吸収促進物質として知られるビタミンC(L−アスコルビン酸)を加えるので、吸収性をさらに向上することができる。
(3)得られた鉄補給組成物は有機酸鉄となっているので胃液(HCl)の影響を受けることなく吸収されるため副作用は殆ど起こらず、吸収性も良いことから、従来のサプリメント(ヘム鉄)よりも貧血などの状態を改善できき、また、食品加工の分野においても品質維持や風味の改善を図ることができ、さらには、家畜や愛玩動物の飼料添加材、鉄欠乏性疾患の予防または治療用などにも供することができる、
など種々の効果を奏するものである。According to the method for producing an iron supplement composition according to the present invention;
(1) After first fermentation with koji mold and sugar added to refined iron raw material and purified water, koji mold, yeast, citric acid bacteria, lactic acid bacteria, acetic acid bacteria alone or a mixture of two or more of these and sugar In addition, the fermented iron raw material is mixed with an organic acid having a carboxyl group selected from citric acid, lactic acid, acetic acid, tartaric acid and malic acid alone, or a mixture of two or more of these. Aged and maintained at a temperature of 35 ° C to 45 ° C, and further filtered and extracted to form an electrolyte state in which the organic acid and iron are dissociated. You can get things.
(2) When an organic acid is added to the fermented iron raw material and ripened, vitamin C (L-ascorbic acid) known as an iron absorption promoting substance is added, so that the absorbability can be further improved.
(3) Since the obtained iron supplement composition is an organic acid iron, it is absorbed without being affected by gastric juice (HCl), so there are almost no side effects and good absorbency. Heme iron can improve conditions such as anemia, and can also maintain quality and improve flavor in the field of food processing. Furthermore, feed additives for livestock and pets, iron deficiency diseases Can also be used for prevention or treatment of
Various effects are exhibited.
次に、本発明に係る鉄補給組成物の製造方法における最良の実施の形態を例示し、以下詳細に説明する。
図1において、本発明に係る鉄補給組成物の製造方法においては、まず、従来公知の手段により微細化した原料鉄粉10を用意し、この原料鉄粉10の重量に対して8倍量〜15倍量の水、好ましくは、上水から塩素などの不純物を除去した精製水12を混合して10分程度煮沸したのち、35℃〜40℃まで冷却する。
次に煮沸処理した原料鉄粉10と精製水12の混合物14に対して10重量%〜30重量%の麹菌16と、この麹菌16と略同量の糖質18を加え加熱ヒータなどで35℃〜40℃で10日ほど保持することにより一次醗酵させる。
この場合、麹菌の添加量が10重量%未満であると充分な醗酵が行われず、また30重量%を超えると量が多すぎて経済性が低下することになる。Next, the best embodiment of the method for producing an iron supplement composition according to the present invention will be exemplified and described in detail below.
In FIG. 1, in the method for producing an iron supplement composition according to the present invention, first, a
Next, 10% by weight to 30% by weight of koji mold 16 and approximately the same amount of
In this case, if the addition amount of the koji mold is less than 10% by weight, sufficient fermentation is not performed, and if it exceeds 30% by weight, the amount is too large and the economy is lowered.
得られた一次醗酵鉄原料20には、糖質18を10重量%程度補填するとともに10重量%〜20重量%の麹菌、酵母、クエン酸菌、乳酸菌、酢酸菌を単独でまたはこれらの2種以上の混合物22を加え、再び35℃〜40℃で10日ほど保持することにより二次醗酵させる。
なお、一次醗酵鉄原料20に加える麹菌、酵母、クエン酸菌、乳酸菌、酢酸菌あるいはこれらの混合物22が10重量%未満であると醗酵が充分行われず、また20重量%を超えると量が多すぎて経済性が低下してしまう。The obtained primary fermented
In addition, fermentation is not sufficiently performed if the koji mold, yeast, citric acid bacteria, lactic acid bacteria, acetic acid bacteria or a
このようにして得られた二次醗酵物24には、10重量%〜40重量%のクエン酸、乳酸、酢酸、酒石酸、リンゴ酸などから選ばれるカルボキシル基を有する有機酸を単独でまたはこれらの2種以上を混合した有機酸26を加えるとともに加熱ヒータなどで35℃〜40℃に保持することにより熟成する。
この場合、クエン酸、乳酸、酢酸、酒石酸、リンゴ酸などのカルボキシル基を有する有機酸あるいは混合有機酸26が10重量%未満であると二次醗酵物22の熟成に時間がかかり、また40重量%を超えると有機酸分が多くなりすぎて酸味が強くなってしまう。The
In this case, when the organic acid having a carboxyl group or mixed
なお、二次醗酵物24の熟成時に、この二次醗酵物24の重量に対して1重量%〜8重量%、好ましくは、5重量%程度のL−アスコルビン酸28を混合する。このようにL−アスコルビン酸26を加えることにより、鉄の吸収性をより高めることができるものである。 In addition, when the
このように35℃〜40℃に保持された二次醗酵物24とL−アスコルビン酸28との混合醗酵物30は、好ましくは、遠赤外線照射下および静電磁場、エレクトロン(−e)供給雰囲気においてゆっくり撹拌しながら流動させることによりさらに10日ほど熟成し、原料鉄10の液化(イオン化)を促進して有機酸中に解離させる。 The mixed fermented
そして、混合醗酵物30中の鉄成分が充分に解離したら、2〜3週間程静置したのち紫外線などにより殺菌し、鉄補給組成物32として濾過抽出する。
この抽出によって得られた鉄補給液状組成物32は、金釘臭ともいわれる独特の鉄臭さや収斂味がほとんどなく、100m中に約2.5%(2454mg)の鉄Feを含有していた。When the iron component in the mixed fermented
The iron-supplemented
実験例
次に、上述の方法により得られた鉄補給組成物32と、非ヘム鉄に比べるとはるかに吸収性の良いヘム鉄を使用したサプリメント鉄剤A(A社製)の吸収性を比較した。 Experimental Example Next, the
具体的には、試料としてのラット(Wister系、8週齢、250g)の頚動脈にカテーテルを挿入して血中クリアランス用のモデルラットを作成した。そしてこれらモデルラットに鉄補給組成物32とサプリメント鉄剤Aをそれぞれ経口投与(3.75mg/250g)し、経時的に採血して血清を分離し、その血清鉄量(Nitroso−PSAP直接法)と血清ヘモグロビン量(SLS−ヘモグロビン法)を測定したのち、トータル鉄から血清ヘモグロビン鉄量を差し引いて血清鉄量(血中鉄量)を計算した。なお、この血清鉄量は、血清の濃度変化を考慮して血清ヘモグロビン量により補正をかけて一定の濃度(初期値)を基準として算出した。また、血清鉄量の測定は、経口投与前(0時間)、経口投与後0.5時間、1時間、2時間、3時間、5時間、8時間まで行い、表1の結果を得た。 Specifically, a model rat for blood clearance was prepared by inserting a catheter into the carotid artery of a rat (Wister system, 8 weeks old, 250 g) as a sample. These model rats were orally administered with
この結果、表1および図2からも明らかなように、血中鉄量は鉄補給組成物32およびサプリメント鉄剤Aのいずれも経口投与後0.5時間で最大となり、鉄補給組成物32の鉄量はサプリメント鉄剤Aの約3倍近くであった。また、サプリメント鉄剤Aの血中鉄量は1時間30分前後にはほぼ通常値に戻ったのに対し、鉄補給組成物32は5時間程度経過してから通常値に戻り、その吸収時間はサプリメント鉄剤Aの4.2倍も長かった。 As a result, as is apparent from Table 1 and FIG. 2, the amount of iron in the blood reached the maximum at 0.5 hours after oral administration of both the
これは、イオン化された鉄は十二指腸や小腸上部で吸収されるためそこでの吸収が良く、鉄補給組成物32は時間経過から推測すると小腸中部から下部にかけても鉄イオンを吸収していることがうかがえる。また、血中鉄量を高濃度に保持していた鉄補給組成物30は、非ヘム鉄といっても有機酸と鉄が解離している電解質の状態のため吸収性が良いからである。 This is because ionized iron is absorbed in the duodenum and upper part of the small intestine, so that the
なお、鉄補給組成物32は、血中鉄量が最大となった0.5時間から30分経後に一度下がり、1時間の間その量を略保持して2時間後からまた低下しているが、これは小腸の上・中・下における吸収の継続なのか、血中の鉄イオンがトランスフェリンやミオゴロビンなどに吸収され貯蔵に回ったものなのか、あるいは、肝臓・脾臓などの貯蔵に回っているものなのか明確ではないが、一般的に吸収性の良好なヘム鉄を使用したサプリメント鉄剤Aに比べ、鉄補給組成物32の吸収性の良さとその持続性に際立った優位性が認められる。従って、従来のサプリメントを使用するよりも少量で負荷もかからずに貧血などの状態をより改善できるものである。 It should be noted that the
先に述べたように本発明方法により得られる鉄補給組成物は、副作用の少ない有機酸と鉄が解離している電解質として構成されているので貧血などの状態を従来のサプリメントを使用したときよりも改善できるだけでなく、食品加工の分野においても0.1%程度の微量を添加して処理することにより対象とする食品の品質維持や風味の改善を図ることができ、また、家畜や愛玩動物の飼料添加材、鉄欠乏性疾患の予防または治療用など種々の分野、用途に供することができるものである。 As described above, the iron supplement composition obtained by the method of the present invention is configured as an electrolyte in which iron is dissociated from an organic acid with few side effects, so that the state of anemia or the like is more than when a conventional supplement is used. In addition to improving the quality of food products, it is possible to improve the quality and flavor of target foods by adding a small amount of about 0.1% in the field of food processing. Can be used in various fields and applications such as feed additives, and prevention or treatment of iron deficiency diseases.
10…原料鉄粉、
12…精製水、
14…原料鉄粉と精製水の混合物、
16…麹菌、
18…糖質、
20…一次醗酵鉄原料、
22…麹菌または麹菌などの混合物、
24…二次醗酵物、
26…有機酸あるいは混合有機酸、
28…L−アスコルビン酸、
30…混合醗酵物、
32…鉄補給組成物、10 ... Raw iron powder,
12 ... purified water,
14 ... A mixture of raw iron powder and purified water,
16 ... Koji,
18 ... sugar,
20 ... Primary fermented iron raw material,
22 ... gonococcus or a mixture of gonococci,
24 ... secondary fermentation product,
26: Organic acid or mixed organic acid,
28 ... L-ascorbic acid,
30 ... Mixed fermented product,
32. Iron supplement composition,
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006064834A JP5028609B2 (en) | 2006-02-13 | 2006-02-13 | Method for producing iron supplement composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006064834A JP5028609B2 (en) | 2006-02-13 | 2006-02-13 | Method for producing iron supplement composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007209324A true JP2007209324A (en) | 2007-08-23 |
JP5028609B2 JP5028609B2 (en) | 2012-09-19 |
Family
ID=38488266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006064834A Active JP5028609B2 (en) | 2006-02-13 | 2006-02-13 | Method for producing iron supplement composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5028609B2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009100725A (en) * | 2007-10-19 | 2009-05-14 | Makoto Yafuji | Method for producing dispersion of ceramides composition |
JP2010090096A (en) * | 2008-10-08 | 2010-04-22 | Makoto Yafuji | Method of manufacturing improved keratin |
JP2010254658A (en) * | 2009-04-24 | 2010-11-11 | Makoto Yafuji | Method for producing antibacterial ionized metal composition |
WO2014042046A1 (en) * | 2012-09-13 | 2014-03-20 | オリエンタル酵母工業株式会社 | High-iron-content yeast extract, method for producing same, and food product |
JP2014200183A (en) * | 2013-04-03 | 2014-10-27 | オリエンタル酵母工業株式会社 | Red rice additive and production method thereof, red rice and production method thereof, and kit for production of red rice additive |
WO2020031141A1 (en) * | 2018-08-10 | 2020-02-13 | Cura Global Health (Bvi) Limited | Method for treating iron deficiency |
CN112220047A (en) * | 2020-10-28 | 2021-01-15 | 江苏海创知识产权服务有限公司 | Ferric pyrophosphate and production process thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004057183A (en) * | 2002-07-31 | 2004-02-26 | Makoto Yafuji | Method for producing agaric mushroom extract |
JP2005041851A (en) * | 2003-07-23 | 2005-02-17 | Makoto Yafuji | Supplement composed mainly of vitamin and bonded with ionized mineral |
JP2005220331A (en) * | 2004-02-04 | 2005-08-18 | Makoto Yafuji | Method for producing low-molecular chitosan |
-
2006
- 2006-02-13 JP JP2006064834A patent/JP5028609B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004057183A (en) * | 2002-07-31 | 2004-02-26 | Makoto Yafuji | Method for producing agaric mushroom extract |
JP2005041851A (en) * | 2003-07-23 | 2005-02-17 | Makoto Yafuji | Supplement composed mainly of vitamin and bonded with ionized mineral |
JP2005220331A (en) * | 2004-02-04 | 2005-08-18 | Makoto Yafuji | Method for producing low-molecular chitosan |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009100725A (en) * | 2007-10-19 | 2009-05-14 | Makoto Yafuji | Method for producing dispersion of ceramides composition |
JP2010090096A (en) * | 2008-10-08 | 2010-04-22 | Makoto Yafuji | Method of manufacturing improved keratin |
JP2010254658A (en) * | 2009-04-24 | 2010-11-11 | Makoto Yafuji | Method for producing antibacterial ionized metal composition |
CN104797702A (en) * | 2012-09-13 | 2015-07-22 | 东方酵母工业株式会社 | High-iron-content yeast extract, method for producing same, and food product |
KR20150056593A (en) * | 2012-09-13 | 2015-05-26 | 오리엔탈 이스트 컴파니 리미티드 | High-Iron-Content Yeast Extract, Method for Producing Same, And Food Product |
WO2014042046A1 (en) * | 2012-09-13 | 2014-03-20 | オリエンタル酵母工業株式会社 | High-iron-content yeast extract, method for producing same, and food product |
JPWO2014042046A1 (en) * | 2012-09-13 | 2016-08-18 | オリエンタル酵母工業株式会社 | High iron content yeast extract, method for producing the same, and food |
CN104797702B (en) * | 2012-09-13 | 2017-07-28 | 东方酵母工业株式会社 | Yeast extract and its manufacture method and food containing High Content Ferric Ion |
TWI629939B (en) * | 2012-09-13 | 2018-07-21 | 東方酵母工業股份有限公司 | High-iron-content yeast extract, method for producing the same, and foods |
KR102196568B1 (en) | 2012-09-13 | 2020-12-29 | 오리엔탈 이스트 컴파니 리미티드 | High-Iron-Content Yeast Extract, Method for Producing Same, And Food Product |
JP2014200183A (en) * | 2013-04-03 | 2014-10-27 | オリエンタル酵母工業株式会社 | Red rice additive and production method thereof, red rice and production method thereof, and kit for production of red rice additive |
WO2020031141A1 (en) * | 2018-08-10 | 2020-02-13 | Cura Global Health (Bvi) Limited | Method for treating iron deficiency |
CN112220047A (en) * | 2020-10-28 | 2021-01-15 | 江苏海创知识产权服务有限公司 | Ferric pyrophosphate and production process thereof |
Also Published As
Publication number | Publication date |
---|---|
JP5028609B2 (en) | 2012-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5028609B2 (en) | Method for producing iron supplement composition | |
Willhite et al. | Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts | |
CN103432161B (en) | Multivitamin mineral effervescent tablet and preparation method thereof | |
KR102057555B1 (en) | Carboxylic Acid Mixtures to Treat Patients with Renal Failure | |
JP6620296B2 (en) | Feed additive composition for reducing methane production in ruminants | |
RU2508409C2 (en) | Sugar-containing product manufacture method | |
JP4596304B2 (en) | Growth hormone secretion promoting composition | |
CN107279296A (en) | A kind of formula food of suitable diabetes and preparation method thereof | |
KR20140067579A (en) | A manufacturing method of overhang solution pellet and overhang solution pellet munufactured by the same | |
CN110122707A (en) | One kind is relieved the effect of alcohol fruit drink and preparation method thereof | |
JP6710098B2 (en) | Nutritional composition and dietary supplement | |
JPH06284872A (en) | Health and beauty promoter, blood pressure suppressor and constipation improver having sod action | |
CN103565811B (en) | Compound vitamin lyophilized preparation for injection and its preparation method | |
JP3761510B2 (en) | Foods that improve or prevent hay fever | |
CN108853476A (en) | A kind of iron protein succinylate oral solution and preparation method thereof | |
JPH11199492A (en) | Production of calcium-supplying agent | |
CN109394788A (en) | Pet is enriched blood liver extract oral liquor and preparation method thereof | |
Ghada et al. | Effect of different types of oral iron therapy used for the treatment of iron deficiency anemia and their effects on some hormones and minerals in anemic rats | |
CN110862900A (en) | Preparation method and application of fruit and vegetable fermentation liquor | |
CN101731627A (en) | Drink or oral liquid capable of supplementing various trace elements | |
CN108652010B (en) | Omega 3 quick solvent and preparation method thereof | |
EP2638913B1 (en) | Method for producing bioactive agent, bioactive agent produced thereby, cosmetic, freshness-maintaining agent, growth promotion agent, soil conditioning agent, and pharmaceutical stock solution | |
JP2002080376A (en) | Biologically active agent and medicine | |
WO2017014153A1 (en) | Cyclic dipeptide-containing anti-obesity composition | |
KR20190014220A (en) | Composition of mixed ferment extraction liquid for hangover elimination and hangover eliminator containing composition as effective ingredient thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090120 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110713 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120322 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120508 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120524 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120531 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120531 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120531 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5028609 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150706 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |